Dr Mark Socinski analyzes data from the CITYSCAPE and COAST studies showing improved ORR and PFS with combinations of novel immunotherapy agents in patients with metastatic or locally advanced/unresectable NSCLC, and from the CheckMate-743 study, in which the combination of nivolumab plus ipilimumab resulted in improved survival over chemotherapy in patients with malignant pleural mesothelioma.
Medical Oncologist, Thoracic Cancer
Executive Medical Director
AdventHealth Cancer Institute
Orlando, FL
Executive Medical Director
AdventHealth Cancer Institute
Orlando, FL
Related Items
Faculty Perspectives: Comprehensive Biomarker Testing in NSCLC: Opportunities to Advance Precision Medicine published on June 27, 2022
Conference Correspondent published on December 16, 2021 in Dual IO 2021 Year in Review
Conference Correspondent published on December 16, 2021 in Dual IO 2021 Year in Review
Conference Correspondent published on December 15, 2021 in Dual IO 2021 Year in Review